Recent advances in liposome formulations for breast cancer therapeutics.

Yang, B; Song, B-P; Shankar, S; Guller, A; Deng, W

Recent advances in liposome formulations for breast cancer therapeutics.

Yang, B Song, B-P Shankar, S Guller, A Deng, W

Permalink

Publisher:: SPRINGER BASEL AG
Publication Type:: Journal Article
Citation:: Cell Mol Life Sci, 2021, 78, (13), pp. 5225-5243
Issue Date:: 2021-07

Closed Access

	Filename	Description	Size
	Yang2021_Article_RecentAdvancesInLiposomeFormul.pdf	Published version	1.78 MB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Yang, B
dc.contributor.author	Song, B-P
dc.contributor.author	Shankar, S
dc.contributor.author	Guller, A
dc.contributor.author	Deng, W https://orcid.org/0000-0002-9413-0978
dc.date.accessioned	2022-05-23T00:45:46Z
dc.date.available	2021-04-30
dc.date.available	2022-05-23T00:45:46Z
dc.date.issued	2021-07
dc.identifier.citation	Cell Mol Life Sci, 2021, 78, (13), pp. 5225-5243
dc.identifier.issn	1420-682X
dc.identifier.issn	1420-9071
dc.identifier.uri	http://hdl.handle.net/10453/157612
dc.description.abstract	Among many nanoparticle-based delivery platforms, liposomes have been particularly successful with many formulations passed into clinical applications. They are well-established and effective gene and/or drug delivery systems, widely used in cancer therapy including breast cancer. In this review we discuss liposome design with the targeting feature and triggering functions. We also summarise the recent progress (since 2014) in liposome-based therapeutics for breast cancer including chemotherapy and gene therapy. We finally identify some challenges on the liposome technology development for the future clinical translation.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	SPRINGER BASEL AG
dc.relation.ispartof	Cell Mol Life Sci
dc.relation.isbasedon	10.1007/s00018-021-03850-6
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 0606 Physiology, 1103 Clinical Sciences
dc.subject.classification	Biochemistry & Molecular Biology
dc.subject.mesh	Animals
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Drug Compounding
dc.subject.mesh	Drug Delivery Systems
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Liposomes
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Liposomes
dc.subject.mesh	Drug Delivery Systems
dc.subject.mesh	Drug Compounding
dc.subject.mesh	Female
dc.subject.mesh	Nanoparticles
dc.title	Recent advances in liposome formulations for breast cancer therapeutics.
dc.type	Journal Article
utslib.citation.volume	78
utslib.location.activity	Switzerland
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	0606 Physiology
utslib.for	1103 Clinical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	closed_access	*
dc.date.updated	2022-05-23T00:45:45Z
pubs.issue	13
pubs.publication-status	Published
pubs.volume	78
utslib.citation.issue	13

Abstract:

Among many nanoparticle-based delivery platforms, liposomes have been particularly successful with many formulations passed into clinical applications. They are well-established and effective gene and/or drug delivery systems, widely used in cancer therapy including breast cancer. In this review we discuss liposome design with the targeting feature and triggering functions. We also summarise the recent progress (since 2014) in liposome-based therapeutics for breast cancer including chemotherapy and gene therapy. We finally identify some challenges on the liposome technology development for the future clinical translation.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/157612